Use of Benzodiazepines in Anxiety Disorders

New England Journal of Medicine

Volumn 328, Issue 19, 1993, Pages 1398-1405

  Wood, Alastair J J ^a   Shader, Richard I ^b   Greenblatt, David J ^b  

^a New England Medical Center Hospital ^*

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; HALAZEPAM; LORAZEPAM; OXAZEPAM; PRAZEPAM;

ANTEROGRADE AMNESIA; ANXIETY NEUROSIS; CLINICAL FEATURE; DROWSINESS; DRUG CHOICE; DRUG DEPENDENCE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; PANIC; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SYMPTOM; TREATMENT PLANNING; UNITED STATES; WITHDRAWAL SYNDROME;

ANXIETY DISORDERS; BENZODIAZEPINES; DRUG TOLERANCE; HUMAN; SUBSTANCE-RELATED DISORDERS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027213217     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199305133281907     Document Type: Review

References (97)

1. Garattini S, Mussini E, Randall LO, eds. The benzodiazepines. New York: Raven Press, 1973.
2. Greenblatt DJ, Shader RI. Benzodiazepines in clinical practice. New York: Raven Press, 1974.
3. Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul SM, eds. Pharmacology of benzodiazepines. London: MacMillan Press, 1982.
4. Greenblatt DJ, Shader RI, Abernethy DR Current status of benzodiazepines. N Engl J Med 1983; 309:354-8, 410
5. Smith DE, Wesson DR, eds. The benzodiazepines: two decades of research and clinical experience. J Psychoactive Drugs 1983; 15:1-157
6. Roy-Byrne PP, Cowley DS, eds. Benzodiazepines in clinical practice: risks and benefits. Washington, D.C.: American Psychiatric Press, 1991.
7. Diagnostic and statistical manual of mental disorders. 3rd ed. rev.: DSM-III-R. Washington, D.C.: American Psychiatric Association, 1987.
8. International classification of diseases. 10th revision (ICD-10). Vol. X. Mental, behavioral, and developmental disorders. Geneva: World Health Organization, 1988.
9. Judd FK, Norman TR, Burrows GD Pharmacological treatment of panic disorder. Int Clin Psychopharmacol 1986; 1:3-16
10. Wilkinson G, Balestrieri M, Ruggeri M, Ballantuono C Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991; 21:991-998
11. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992; 160:191-202
12. Uhlenhuth EH, Balter MB, Mellinger GD, Cisin IH, Clinthorne J Symptom checklist syndromes in the general population. Arch Gen Psychiatry 1983; 40:1167-1173
13. Regier DA, Boyd JH, Burke JD Jr, One-month prevalence of mental disorders in the United States: based on five epidemiologic catchment area studies. Arch Gen Psychiatry 1988; 45:977-986
14. Reich J The epidemiology of anxiety. J Nerv Ment Dis 1986; 174:129-136
15. Shader RI, Goodman M, Gever J Panic disorders: current perspectives. J Clin Psychopharmacol 1982; 2: Suppl: 2S-10S
16. Noyes R Jr, Clancy J, Hoenk PR, Slymen DJ The prognosis of anxiety neurosis. Arch Gen Psychiatry 1980; 37:173-178
17. Pollack MH, Otto MW, Rosenbaum JF, Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990; 51: Suppl A: 12-16
18. Angst J, Vollrath M The natural history of anxiety disorders. Acta Psychiatr Scand 1991; 84:446-452
19. Markowitz JS, Weissman MM, Ouellette R, Lish LD, Klerman GL Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46:984-992
20. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S Panic attacks in the community: social morbidity and health care utilization. JAMA 1991; 265:742-746
21. Croft-Jeffreys C, Wilkinson G Estimated costs of neurotic disorder in UK general practice 1985. Psychol Med 1989; 19:549-558
22. Katon WJ, Von Korff M, Lin E Panic disorder: relationship to high medical utilization. Am J Med 1992; 92: Suppl 1A: 7S-11S
23. Cowley DS Alcohol abuse, substance abuse, and panic disorder. Am J Med 1992; 92: Suppl 1A: 41S-48S
24. Otto MW, Pollack MH, Sachs GS, O'Neil CA, Rosenbaum JF Alcohol dependence in panic disorder patients. J Psychiatr Res 1992; 26:29-38
25. Salmons P, Sims A Smoking profiles of patients admitted for neurosis. Br J Psychiatry 1981; 139:43-46
26. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997
27. Breslau N, Kilbey MM, Andreski P Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991; 48:1069-1074
28. Allgulander C, Lavori PW Excess mortality among 3302 patients with ‘pure’ anxiety neurosis. Arch Gen Psychiatry 1991; 48:599-602
29. Weissman MM, Klerman GL, Markowitz JS, Ouellette R Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 1989; 321:1209-1214
30. Noyes R Jr Suicide and panic disorder: a review. J Affect Disord 1991; 22:1-11
31. Mellinger GD, Balter MB, Uhlenhuth EH Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984; 251:375-379
32. Parry HJ, Balter MB, Mellinger GD, Cisin IH, Manheimer DI National patterns of psychotherapeutic drug use. Arch Gen Psychiatry 1973; 28:769-783
33. Balter MB, Levine J, Manheimer DI Cross-national study of the extent of anti-anxiety/sedative drug use. N Engl J Med 1974; 290:769-774
34. Woods JH, Katz JL, Winger G Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44:151-347
35. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 1983; 14:251-292
36. Greenblatt DJ, Shader RI. Pharmacokinetics of antianxiety agents. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1377-86.
37. Greenblatt DJ, Shader RI. Pharmacotherapy of anxiety with benzodiazepines and β-adrenergic blockers. In: Lipton MA, DiMascio A, Killam KF, eds. Psychopharmacology: a generation of progress. New York: Raven Press, 1978:1381-90.
38. Munjack DJ, Crocker B, Cabe D, Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989; 9:22-27
39. Ballenger JC, Burrows GD, DuPont RL Jr, Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45:413-422
40. Noyes R Jr, Anderson DJ, Clancy J, Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41:287-292
41. Schweizer E, Fox I, Case G, Rickels K Lorazepam vs. alprazolam in the treatment of panic disorder. Psychopharmacol Bull 1988; 24:224-227
42. Charney DS, Woods SW Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50:418-423
43. Tesar GE, Rosenbaum JF, Pollack MH, Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52:69-76
44. Ciraulo DA, Antal EJ, Smith RB, The relationship of alprazolam dose to steady-state plasma concentrations. J Clin Psychopharmacol 1990; 10:27-32
45. Ciraulo DA, Barnhill JG, Boxenbaum HG, Greenblatt DJ, Smith RB Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorders. J Clin Pharmacol 1986; 26:292-298
46. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149:1556-1562
47. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry (in press).
48. Greenblatt DJ, Laughren TP, Allen MD, Harmatz JS, Shader RI Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol 1981; 11:35-40
49. Bowden CL, Fisher JG Relationship of diazepam serum level to antianxiety effects. J Clin Psychopharmacol 1982; 2:110-114
50. Tyrer P, Treasaden I, Moreton K, Riley P, Flanagan RJ, Dawling S Value of serum diazepam and nordiazepam measurements in anxious patients. J Affect Disord 1984; 7:1-10
51. Rickels K, Case WG, Downing RW, Dixon R, Fridman R Diazepam and desmethyldiazepam plasma concentrations in chronic anxious outpatients. Pharmacopsychiatry 1984; 17:44-49
52. Rickels K, Schweizer E, Case WG, Greenblatt DJ Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47:899-907 [Erratum, Arch Gen Psychiatry 1991;48:51.]
53. Rickels K, Fox IL, Greenblatt DJ, Sandler KR, Schless A Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 1988; 145:312-317
54. Friedman H, Greenblatt DJ Rational therapeutic drug monitoring. JAMA 1986; 256:2227-2233
55. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM Characteristics of long-term alprazolam users in the community. J Clin Psychopharmacol 1992; 12:316-321
56. Cohn JB, Wilcox CS Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984; 4:93-98
57. Murphy SM, Owen R, Tyrer P Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry 1989; 154:529-534
58. Fabre LF, McLendon DM, Stephens AG Comparison of the therapeutic effect, tolerance and safety of ketazolam and diazepam administered for six months to out-patients with chronic anxiety neurosis. J Int Med Res 1981; 9:191-198
59. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45:444-450
60. Rickels K, Case WG, Downing RW, Winokur A Long-term diazepam therapy and clinical outcome. JAMA 1983; 250:767-771
61. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315:854-859
62. Rickels K, Case WG, Diamond L Relapse after short-term drug therapy in neurotic outpatients. Int Pharmacopsychiatry 1980; 15:186-192
63. Rickels K, Case WG, Downing RW, Fridman R One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol 1986; 6:32-36
64. Rickels K, Case WG, Schweizer E, Garcia-Espana F, Fridman R Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991; 148:757-761
65. A-benzodiazepine receptor: biology and pharmacology. In: Burrows GD, Roth M, Noyes R, eds. Handbook of anxiety. Vol. 3. The neurobiology of anxiety. Amsterdam: Elsevier, 1990:165-88.
66. Zorumski CF, Isenberg KE Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry 1991; 148:162-173
67. Miller LG, Greenblatt DJ, Paul SM, Shader RI Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 1987; 240:516-522
68. Hindmarch I, Kerr JS, Sherwood N The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcohol 1991; 26:71-79
69. Greenblatt DJ, Harmatz JS, Shapiro L, Englehardt N, Gouthro TA, Shader RI Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324:1691-1698
70. Ellinwood EH Jr, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology (Berl) 1985; 86:392-399
71. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl) 1984; 84:452-456
72. Linnoila M, Erwin CW, Brendle A, Simpson D Psychomotor effects of diazepam in anxious patients and healthy volunteers. J Clin Psychopharmacol 1983; 3:88-96
73. King DJ Benzodiazepines, amnesia and sedation: theoretical and clinical issues and controversies. Human Psychopharmacol 1992; 7:79-87
74. Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986; 39:526-529
75. Roth T, Roehrs T, Wittig R, Zorick F Benzodiazepines and memory. Br J Clin Pharmacol 1984; 18: Suppl 1: 45S-49S
76. Lister RG The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985; 9:87-94
77. Ghoneim MM, Mewaldt SP Benzodiazepines and human memory: a review. Anesthesiology 1990; 72:926-938
78. Curran HV Benzodiazepines, memory and mood: a review. Psychopharmacology (Berl) 1991; 105:1-8
79. A receptor function. J Pharmacol Exp Ther 1988; 246:170-176
80. Hall RCW, Zisook S Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981; 11: Suppl 1: 99S-104S
81. Dietch JT, Jennings RK Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988; 49:184-188
82. Hollister LE, Motzenbecker FP, Degan RO Withdrawal reactions from chlordiazepoxide (“Librium”). Psychopharmacologia 1961; 2:63-68
83. Marks J. The benzodiazepines: use, overuse, misuse, abuse. Lancaster, England: MTP Press, 1985.
84. Woods JH, Katz JL, Winger G Abuse liability of benzodiazepines. Pharmacol Rev 1987; 39:251-419 [Erratum, Pharmacol Rev 1988;40:85.]
85. Woods JH, Katz JL, Winger G Use and abuse of benzodiazepines: issues relevant to prescribing. JAMA 1988; 260:3476-3480
86. Roy-Byrne PP, Hommer D Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med 1988; 84:1041-1052
87. Noyes R Jr, Garvey MJ, Cook BL, Perry PJ Benzodiazepine withdrawal: a review of the evidence. J Clin Psychiatry 1988; 49:382-389
88. Tyrer P Dependence as a limiting factor in the clinical use of minor tranquillizers. Pharmacol Ther 1988; 36:173-188
89. Benzodiazepine dependence, toxicity, and abuse. Washington, D.C.: American Psychiatric Association, 1990.
90. Lader M Dependence on benzodiazepines. J Clin Psychiatry 1983; 44:121-127
91. de Wit H, Griffiths RR Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 1991; 28:83-111
92. Rifkin A, Doddi S, Karajgi B, Hasan N, Alvarez L Benzodiazepine use and abuse by patients at outpatient clinics. Am J Psychiatry 1989; 146:1331-1332
93. Lucki I, Rickels K, Geller AM Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berl) 1986; 88:426-433
94. Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JBW Substance-use disorders in DSM-III-R: evidence for the dependence syndrome across different psychoactive substances. Br J Psychiatry 1987; 151:834-843
95. Fontaine R, Chouinard G, Annable L Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984; 141:848-852
96. Greenblatt DJ, Miller LG, Shader RI Benzodiazepine discontinuation syndromes. J Psychiatr Res 1990; 24: Suppl 2: 73-79
97. Higgitt A, Fonagy P, Toone B, Shine P The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria? Acta Psychiatr Scand 1990; 82:165-168